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Objectives: Our study is comparing the effectiveness of 7.5% Povidone-iodine with 1% Clotrimazole ear drops 
and lignocaine in the management of Otomycosis to highlight the importance of replacing conventional 
antifungals in routine practice. 
Setting: Department of ENT and Head and Neck Surgery, Holy Family Hospital, Rawalpindi, Pakistan. 
Study design: A prospective randomized control trial  
Methodology: This study was conducted for 12 months in our institute from July 2014 to June 2015. A total 
number of 148 patients with clinically diagnosed Otomycosis between the ages group 15 to 55 years were studied. 
All patients with a clinical diagnosis of Otomycosis presenting with all four features of earache, itching, ear-
blockage, and ear discharge in ENT OPD were included. Ear swabs were taken and sent for fungal culture. 
Patients were divided into A and B groups each comprising of 74 patients. Group A received 1% Clotrimazole ear 
drops and lignocaine and group B received 7.5% Povidone-iodine for 14 days after the results of cultures were 
received. At the end of 14 days, patients of both groups were compared based on the resolution of symptoms and 
signs. 
Results: At the end of 14 days, 32 out of 74 patients (43%) in group A receiving 1% Clotrimazole ear drops and 
lignocaine reported resolution of all symptoms, and 52 out of 74 patients (70%) showed complete resolution of all 
signs, while in group B,68 out of 74 patients (91%) showed complete resolution of symptoms and 69 out of 74 
patients (93%) showed complete resolution of signs. Our study showed significant improvement in signs and 
symptoms of Otomycosis achieved by treatment with 7.5% Povidone-iodine compared to that achieved by 1% 
Clotrimazole ear drops and lignocaine. 
Conclusion: 7.5% Povidone-iodine is a more effective antifungal agent in the treatment of Otomycosis as 
compared to 1% Clotrimazole ear drops and lignocaine. 
Keywords: Otomycosis, Povidone-iodine, Clotrimazole. 





Otomycosis is a superficial fungal infection of the 
external auditory canal and is worldwide in 
distribution characterized by inflammation, pruritus, 
scaling, and severe discomforts like suppuration and 
pain.¹ This disease can also spread to the middle ear if 
the tympanic membrane is perforated.² It is usually 
unilateral and more common in the younger age 
group². It is estimated that almost 5% to 25% of total 
cases of Otitis Externa (inflammation of the external 
auditory canal) are due to Otomycosis.³ It is common 
in a hot and humid climate like the south Asian region, 
mostly in people belonging to lower socioeconomic 
backgrounds.³ The most common causative agent 
isolated from Otomycosis patients is from the genus 
Aspergillus followed by Candida Species. Among the 
genus Aspergillus, Aspergillus niger is most common 
followed by A.flavus and A.fumigatus.⁴  
In patients of Otomycosis, debris in the external 
auditory canal does not always consist of purely 
fungal elements but is mixed with bacterial invaders 
like Pseudomonas aeruginosa, Staphylococcus, and 
Streptococcus.⁵ Otoscopic examination reveals a 
grayish-white mass in the external auditory canal 
along with hyperemia and sometimes edema as well. 
Patients commonly present with pain and itching in 
the ear.⁶ The diagnosis of Otomycosis is based on 
history, otoscopic examination, and fungal culture. 
Direct preparation of the specimen specifically with 
optic brightener, mycological culture, and histological 
examination is strongly recommended for correct 
diagnosis. The microscopic examination of fungal 
cultures after the preparation of slides with Potassium 
hydroxide shows discrete clumps of hyphae with 
conidiophores.⁷ 
Many pharmacological preparations like drugs from 
Azole class, Nystatin, 7.5% Povidone-iodine, 
Tolnaftate, Acetic acid, and Gention violet are 
currently used widely for the treatment of Otomycosis 
without knowing the exact efficacy of drug class.⁸ 
Further studies are required to find out the antifungal 
activity of each class of drugs and the comparison of 
their resistance patterns in detail to aid in evidence-
based decision-making to prevent the potential risk of 
antifungal resistance which not only increases disease 
burden but is also cost-intensive. 
The purpose of this study is to evaluate the antifungal 
property of 7.5% Povidone-iodine to promote an 
alternate, effective and cheaper treatment of 
Otomycosis. Povidone-iodine has effective 
antibacterial, antifungal, and antiprotozoal properties. 
Previous studies have shown promising results of the 
antifungal activity of Povidone-iodine in the treatment 
of Otomycosis. We want to evaluate whether the same 
is true in our population and the comparative pros and 
cons of using it instead of 1% Clotrimazole ear drops 
and lignocaine preparation. 
 
Materials and Methods 
 
A randomized control trial was conducted in our 
institution for 12 months. The institutional research 
board clearance was taken before the commencement 
of the study and detailed informed consent was also 
taken from the subjects. All the patients with clinically 
diagnosed Otomycosis within the age range of 15 to 55 
years were included in the study. Patients with 
Chronic Suppurative Otitis, Media, Malignant Otitis 
Externa, post-operative mastoidectomy cavities, and 
Diabetes Mellitus were excluded from this study. All 
the patients who presented to us through OPD with 
symptoms of earache, itching, ear blockage, and ear 
discharge were included. These patients were 
diagnosed based on history, examination with an 
otoscope, and fungal culture of ear swab taken. The 
cultures were grown on Sabouraud Dextrose agar at 
25⁰C and incubated for 24 hours. We also did an aural 
toilet with a suction machine. Otoscope and suction 
machines were the main instruments used to aid in the 
diagnosis of Otomycosis in our research. The 
symptoms and signs of these patients were 
documented after taking written informed consent 
from each of them. We divided the patients into two 
equal groups: A and B, comprising of 74 patients in 
each group. Group A received 1% Clotrimazole ear 
drops and lignocaine drops, 3 drops each to be 
instilled in the affected ear three times a day for 14 
days. Group B received 7.5% Povidone-iodine ear 
drops also prescribed as 3 drops thrice a day for 14 
days. The evaluation of patients in both the groups 
was done on the 14th day based on the resolution of 
symptoms and signs however on the 7th day all the 
patients were called for the suction toilet to clear the 
fungal debris. Data was analyzed and entered using 
SPSS version 18. 
Target sample size and rationale: 
The sample size was calculated using the WHO 
sample size calculator, keeping the power of test 90% 
level of significance 5%, resolution of otalgia in 
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In this study, out of a total of 148 patients, there were 
46 (62.16%) males and 28 (37.8%) females in group A. 
In group B there were 51 (68.91%) males and 23 
(31.01%) females. The male to female ratio in group A 
was1.6:1 and in group B was 2.2:1. The graphical 
representation of gender distribution is shown in fig.1 
below. According to the culture results from ear 
swabs, Aspergillus Niger was isolated in 63% of 
culture results whereas Candida albicans were 
detected in 33% of cultures from both the groups. 
The number of patients with persisting symptoms of 
earache, itching, ear blockage, and ear discharge in 
group A after 14 days of treatment was 35 (47%), 42 
(57%), 31 (42%), 38 (51%) respectively out of a total of 
74 patients, while in group B the number of patients 
with these persisting symptoms was 4 (54%), 3 (41%), 
5 (67%)and 6 (8%) patients respectively as shown in 
Figure 2 and Table 1. 
Signs of fungal debris, erythema of canal, and 
erythema of tympanic membrane persisting after 14 
days were seen in 20 (27%), 22 (30%), and 7 (9%) 
patients respectively in group A while in group B they 
were seen in 2 (2.7%), 5 (6.7%) and 1 (1.3%) patients 
respectively out of a total of 72 patients in both groups 




Figure 1: Male to Female ratio graph 
 
 















P value  
Otalgia 35 (47 %) 4 (5.4%) 0.042 
Pruritus 42 (57%) 3 (4%) 0.031 
Ear blockage 31 (42 %) 5 (6.7%) 0.023 






Figure 2: Comparison of post-treatment symptoms of 
both groups 
 


















20 (27%) 2 (2.7%) 0.045 
Erythema 
of canal 





7 (9%) 1 (1.3%) 0.812 
(n=148) 
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The treatment of Otomycosis has often been presented 
as a clinical challenge in many ENT practices. 
Munguia et al found that Aspergillus species and 
Candida albicans are the most common causative 
organisms.¹² Our study also found that Aspergillus 
species and Candida albicans are the most prevalent 
causative organism in our sample population. Many 
drugs have been investigated for the treatment of 
Otomycosis.⁸ Antifungals from the Azole class seem to 
be the most effective, followed by Nystatin and 
Tolnaftate.¹² 1% Clotrimazole ear drops and lignocaine 
have been used for effective treatment of Otomycosis 
for a long time in the medical field.¹º  Nneenia Mgbor 
et al used Clotrimazole in a comparative study in 
Nigeria and found it to be an effective drug.¹¹ Recently 
some researchers have also studied the efficacy of 
Povidone-iodine in Otomycosis treatment. In our 
clinical practice, we found that most patients do not 
show complete resolution of signs and symptoms of 
Otomycosis with the Azole group of antimycotics like 
Clotrimazole. This leads to treatment failure and 
frequent relapses due to the persistence of spores as 
well as the risk of developing serious complications 
like tympanic membrane perforation, hearing loss, and 
invasive temporal bone infection, although seen 
sporadically and only in immunocompromised 
patients.18 It is because Clotrimazole eardrops are 
irritating, if used alone compliance is difficult to 
achieve by prescribing additional lignocaine drops; 
hence there is the need for studying newer agents. 
Frequent use of the Azole group of antifungals might 
be the main factor for its increased resistance 
worldwide. Van der Linden et al performed a 
prospective nationwide multicenter surveillance study 
in Netherland and found that there was statistically 
significant resistance to the Azole group of antifungals 
in Otomycosis.¹³ In another study acquired azole 
resistance in Aspergillus fumigatous was detected in 
11 out of 17 European centers in 9 countries.15 The 
overall prevalence of Azole group resistance was 3.2% 
which was also associated with worse patient 
outcomes.14,15 
Povidone-iodine (PVP-I) also known as iodopovidone 
is an antiseptic used for skin disinfection before and 
after surgical procedures. Maral Gharaghani et al used 
Povidone-iodine in their study and reported it to be an 
effective antifungal agent.16 Ajay Philip et al 
conducted a comparative study and also observed its 
effectiveness in the management of Otomycosis⁸. Pain, 
pruritis, and ear discharge are the most troublesome 
symptoms reported after Otomycosis which were 
relieved earlier in the group receiving Povidone-iodine 
compared to that receiving Clotrimazole.17 Povidone-
iodine is an inexpensive, nontoxic agent with good 
antimycotic properties and no drug resistance 
reported so far. In developing countries like Pakistan 
where cost-effectiveness is a serious issue, it is very 
important to study and advocate the use of cheaper 
and effective treatments like Povidone-iodine on a 
larger scale by ENT practitioners. Only a few studies 
have been conducted in this regard in Pakistan.  
Our study also confirms a better resolution of signs 
and symptoms of Otomycosis with 7.5% Povidone-
iodine compared to 1% Clotrimazole ear drops and 
lignocaine.  Approximately one-third of patients 
(39.7%) in the 1% Clotrimazole eardrops and 
lignocaine receiving group were not cured. On the 
other hand, only 6.7% of patients in the 7.5% 
Povidone-iodine receiving group had treatment failure 
at the end of 14 days. This proves that 7.5% Povidone-
iodine is significantly better than 1% Clotrimazole ear 
drops and lignocaine in the treatment of Otomycosis 
and future ENT consultants and specialists should 
prescribe it to the patients who are having fungal 




7.5% Povidone-iodine is far effective in the treatment 
and management of Otomycosis as compared to 1% 
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